CD8A and melanoma: To test how blockade of either PI3Kγ and/or PI3Kδ catalytic subunits impacts T cell immunity, peptide‐activated anti‐melanoma pmel‐1 transgenic CD8+ T cells were IL‐2 expanded and simultaneously treated with drugs that inhibit either PI3Kγ (IPI‐549), PI3Kδ (CAL‐101 or TGR‐1202), or both PI3Kγ and PI3Kδ subunits (IPI‐145) for 1 week (Note: T cells expanded with 1 μM CAL‐101 were not therapeutic in mice while those expanded with 10 μM CAL‐101 were [35].